Cabaletta Bio, Inc. financial data

Symbol
CABA on Nasdaq
Location
2929 Arch Street, Suite 600, Philadelphia, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 448 % -61.3%
Debt-to-equity 29.2 % +188%
Return On Equity -107 % -114%
Return On Assets -83 % -82.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 96.3M shares +97%
Common Stock, Shares, Outstanding 96.3M shares +97.1%
Entity Public Float 350M USD -29.2%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 1.17M shares -71.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 132M USD +48.2%
General and Administrative Expense 31.4M USD +23.5%
Operating Income (Loss) -163M USD -42.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -159M USD -52.2%
Earnings Per Share, Basic -2 USD/shares -17.7%
Earnings Per Share, Diluted -2 USD/shares -17.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60.2M USD -64.7%
Cash, Cash Equivalents, and Short-term Investments 160M USD -12.6%
Assets, Current 165M USD -11.3%
Property, Plant and Equipment, Net 2.06M USD -26.7%
Operating Lease, Right-of-Use Asset 3.6M USD -73.6%
Other Assets, Noncurrent 3.61M USD +45.3%
Assets 190M USD -7.17%
Accounts Payable, Current 8.27M USD +279%
Employee-related Liabilities, Current 6.76M USD +32.1%
Liabilities, Current 45.7M USD +99.9%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 50.3M USD +66.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 23K USD +2200%
Retained Earnings (Accumulated Deficit) -475M USD -50.1%
Stockholders' Equity Attributable to Parent 139M USD -20%
Liabilities and Equity 190M USD -7.17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.8M USD -28.4%
Net Cash Provided by (Used in) Financing Activities -552K USD -108%
Net Cash Provided by (Used in) Investing Activities -785K USD +3.33%
Common Stock, Shares Authorized 300M shares +100%
Common Stock, Shares, Issued 96.3M shares +97.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -32.1M USD -79.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 208K USD
Deferred Tax Assets, Valuation Allowance 111M USD +52.6%
Deferred Tax Assets, Gross 115M USD +54.9%
Operating Lease, Liability 0 USD
Depreciation 485K USD +23.4%
Payments to Acquire Property, Plant, and Equipment 785K USD -3.33%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -159M USD -52.2%
Lessee, Operating Lease, Liability, to be Paid 3.63M USD -76.2%
Property, Plant and Equipment, Gross 8.25M USD +30.2%
Operating Lease, Liability, Current 3.63M USD -54.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 200K USD -88.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 1.25M USD +120%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.94M USD +172%
Operating Leases, Future Minimum Payments Due 5.02M USD -2.34%
Interest Expense 2.2M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%